Teva wins battle with Pfizer over Viagra patent
The Supreme Court of Canada on Thursday said that Pfizer’s blockbuster patent on the erectile dysfunction drug Viagra is invalid, reversing a Federal Court ruling that blocked Teva's application to market generic Viagra under the Patented Medicines (Notice of Compliance) Act (PM[NOC])
The decision is interesting in that the Supreme Court took the step of finding the patent invalid, rather than simply allowing the Canadian Minister of Health to grant the notice of compliance, said...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.